Latest news about Unjha Formulations
Unjha Formulations
19.50
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M-9.30%
6M-20.25%
1Y-15.55%
5Y+105.70%
More news about Unjha Formulations
05Feb 26
Unjha Formulations Publishes Q3FY26 Financial Results in Newspapers
Unjha Formulations Limited announced the newspaper publication of its Q3FY26 unaudited financial results on February 5, 2026, in Free Press (English) and Lokmitra (Gujarati) editions. The results show Q3FY26 net sales of ₹440.77 lacs with 17.15% growth and net profit of ₹23.97 lacs. For nine months, the company reported revenue of ₹1230.71 lacs and profit of ₹144.75 lacs, demonstrating strong performance and regulatory compliance.
11Nov 25
Unjha Formulations Reports Profit Turnaround in Q2 Despite Revenue Dip
Unjha Formulations Limited reported a profit of Rs 81.78 lacs in Q2 FY2026, a 109.75% increase from the previous quarter and a turnaround from a loss in Q2 FY2025. Net sales rose to Rs 428.53 lacs, up 18.57% quarter-on-quarter and 13.31% year-on-year. The company's total income increased by 19.63% to Rs 434.74 lacs, while total expenditure was effectively managed, decreasing 9.90% year-on-year. The EPS improved to 1.83, up from -0.25 in the same quarter last year. For the half-year, the company's net sales reached Rs 789.94 lacs with a profit of Rs 120.78 lacs, more than doubling from the previous year.
01Oct 25
Unjha Formulations Appoints Siddharth Shah as Company Secretary and Compliance Officer
Unjha Formulations Limited has appointed Mr. Siddharth Shah as its new Company Secretary and Compliance Officer, effective October 1, 2025. The decision was made during a board meeting on the same date. Mr. Shah, an Associate Member of ICSI with membership number A67232, brings over five years of experience in compliance, insolvency, finance, taxation, and corporate laws. The appointment aligns with Section 203 of the Companies Act, 2013 and Regulation 6 of SEBI Listing Obligations.
06Aug 25
Unjha Formulations Reports Q1 Loss Amid Rising Expenses
Unjha Formulations Limited announced a net loss of Rs. 40.64 lakhs for the first quarter, compared to a profit of Rs. 50.76 lakhs in the same period last year. Total income decreased to Rs. 363.40 lakhs from Rs. 395.43 lakhs year-over-year, while total expenses rose to Rs. 325.81 lakhs from Rs. 272.54 lakhs. The company's Earnings Per Share (EPS) turned negative at Rs. 0.91, down from positive Rs. 1.56 in the previous year's quarter. Despite a 5.01% decrease in material costs and a 24.64% reduction in employee benefits expenses, other expenses increased by 76.79%, contributing to the overall loss.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,789.90
(-0.37%)
6,533.00
(-0.31%)
4,317.90
(-0.75%)
1,379.30
(-0.79%)
1,078.30
(-1.18%)
1,274.00
(-1.27%)
2,249.80
(-0.58%)
2,299.00
(-0.91%)
1,429.20
(-0.31%)
1,382.60
(-0.42%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
